Myriam Lucia Hernandez-Rojas, MD (Mexico City, Jose Dalma- Weiszhausz, MD (MexicoCity, Mexico), Hugo Quiroz- Mercado, MD (Mexico City, Mexico), Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Maura Abraham-Marin, MD (Mexico City, Mexico), Adriana Solis-Vivanco, MD (Mexico City,
Mexico), Elizabeth Reyna-Castelan, MD (Mexico City, Mexico), Jose Luis Guerrero-Naranjo,MD (Mexico City, Mexico), Juan  Manuel Jimenez-Sierra, MD (Mexico City, Mexico), Virgilio Morales-Canton, MD (Mexico City, Mexico)


To determine the safety and efficacy of intravitreal Bevacizumab in the treatment of subfoveal choroidal neovascularization in pathologic myopia.


Prospective interventional case series. Fourteen patients with subfoveal choroidal neovascularization due to pathologic myopia were treated with 0.1ml (2.5 mg) of intravitreal bevacizumab and followed for at least 3 months. Safety, clinical appearance, best corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography (FA)
and physical examination including systemic blood pressure were recorded. Indications for retreatment were an active leaking CNV by FA and OCT in combination with visual disturbances or visual loss.


Fourteen patients were included, ten patients were female (71.4%), mean age was 53.86± 16.26 years old (29 to 85). Mean spherical equivalent was -13.87± 3.68 Diopters (D) (-7.25 to -20.50 D). Mean follow-up was 3 months. There were no serious ocular or systemic adverse events. The mean initial visual acuity was 20/200 that improves to 20/100 two weeks after injection, 20/80 during the four week, 20/60 at eight weeks, the same value until we reach the twelve weeks follow-up (p=0.007; p=0.001; p=0.005; p=0001, respectively). Initial foveal thickness improved from 385.43 μm ± 125.83 μm to 257.64±76.6 μm and 194.54±54.35 μm after first and third month respectively (Wilcoxon signed rank test p=0.001).


Intravitreal bevacizumab is safe. Statistically significant improvement was demonstrated regarding BCVA and foveal thickness. A controlled study and longer follow-up are needed to determine its true usefulness.